BACKGROUND Current guidelines suggest that all patients with acute deep venous thrombosis should be treated with intravenous heparin for at least 5 days, overlapping with warfarin sodium for 4 to 5 days. METHODS Using linked state of California hospital discharge records from 1991 to 1994 we identified patients with acute deep venous thrombosis without pulmonary embolism, and determined the 6...

Abstract A 78 years old woman presented in our cardio–oncology out–patient clinic to renew apixaban treatment plan. In her medical history she was a former smoker, with chronic kidney disease IIIb stadium according KDIGOI guidelines creatinine of 1,54 mg/dl, GFR CKD 32 ml/min/1.73m2 and Cockcroft e Gault 28 ml/min/1.73m2. 2010, had right lobe pulmonary cancer diagnosis treated neo–adjuvant gemc...

Warfarin is an effective preventative treatment for arterial and venous thromboembolism, but requires individualised dosing due to its narrow therapeutic range high individual variation. Many machine learning techniques have been demonstrated in this domain. This study evaluated the accuracy of most promising algorithms on International Pharmacogenetics Consortium dataset a novel clinical South...

OBJECTIVE We examined the potential effect of sex and age on warfarin dosing in ambulatory adult patients. METHODS We conducted a retrospective chart review of patients attending an anticoagulation clinic. We included patients anticoagulated with warfarin for atrial fibrillation or venous thromboembolism who had a therapeutic international normalized ratio of 2-3 for 2 consecutive months. We ...

We respond to comments by Dufrost et al. about the RAPS trial, in particular, showing that the trial did achieve its target sample size; pointing out that thrombin potential is not synonymous with overall thrombin generation; confirming that overall, no increased thrombotic risk was evident comparing rivaroxaban with warfarin; and that high-risk patients (28% were triple positive, representativ...

BACKGROUND Venous thromboembolism comprising pulmonary embolism and deep vein thrombosis is a common condition with an incidence of approximately 1 per 1,000 per annum causing both mortality and serious morbidity. The principal aim of treatment of a venous thromboembolism with heparin and warfarin is to prevent extension or recurrence of clot. However, the recurrence rate following a deep vein ...

conclusions invasive treatment of dialysis patients for cvc related complications is effective and durable during mid-term follow up with no re-intervention, clinical episode of vte or death. cta is a reliable mean for the diagnosis of cvc related complications. methods this is a retrospective analysis of prospectively collected data of dialysis patients treated for cvc-related complications an...

OBJECTIVE To determine whether antithrombotic therapy with warfarin is effective and safe in patients who developed venous thromboembolism in the acute stage of polytrauma, which is associated with bleeding risk. METHOD A retrospective study of 11 patients (8 males, 3 females; mean age, 39.8 years; injury severity score, 30.1; no fatalities) with deep venous thromboembolism and/or pulmonary e...

OBJECTIVE The purpose of this study was to analyze the difference in duration of anticoagulation and dose of warfarin required to reach a therapeutic international normalized ratio [(INR) of 2 to 3] in patients with hypercoagulable conditions as compared to controls. To our knowledge, this study is the first in the literature to delineate such a difference. MATERIALS AND METHODS A retrospecti...

Patients with antiphospholipid syndrome are at increased risk for recurrent arterial and venous thrombosis and therefore benefit from long term warfarin therapy. The optimal duration of warfarin therapy after a first venous thromboembolic event is however a matter of some controversy and many questions remain unanswered. After reviewing and analysing the available evidence, we discuss some comm...